Japanissa Parkinsonin taudin soluterapiat etenee.
" The committee also approved Amchepry, a candidate treatment for Parkinson’s disease developed by Japanese drugmaker Sumitomo Pharma."
“To deliver treatments as quickly as possible, both products have been granted conditional and time-limited approval based on the likelihood of their efficacy, allowing them to be sold provisionally. Further testing will be needed to demonstrate safety and efficacy, and the companies will need to apply for ongoing approval within seven years.”